Agennix AG (Agennix)

Oncology Corporate Profile

HQ Location

101 College Road East
Princeton, NJ 8540

Company Description

Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company_†_s most advanced program is talactoferrin, a first-in class oral Dendritic Cell Mediated Immunotherapy (DCMI). Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing for cancer, and a topical gel form of talactoferrin for diabetic foot ulcers.

Website: http://www.agennix.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
talactoferrinimmunomodulatory protienNon Small Cell Lung Cancer (NSCLC)III
RGB-286638multi-targeted protien kinase inhibitorVarious cancer typesI

View additional information on product candidates here »

Pipeline image

Source


http://www.agennix.com/

Recent News Headlines

There are no news items to display